Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 12/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | PDE1A | P54750 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16174469 | 0.87 | MET (0.43) | METKDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL863990 | 0.79 | MET (0.42) | METCYP3A4KDM4EALDH1A1HPGD | |
| SCHEMBL863987 | 0.78 | MET (0.46) | METCYP3A4KDM4EALDH1A1HPGD | |
| SCHEMBL16174464 | 0.73 | MAOB (0.43) | METL3MBTL1BRD4 | |
| SCHEMBL864043 | 0.73 | MET (0.43) | METCYP3A4PDE1APDE4CPDE4D | |
| SCHEMBL15364821 | 0.67 | ALDH1A1 (0.50) | CYP3A4KDM4EALDH1A1HPGDALOX15 | |
| SCHEMBL17886151 | 0.67 | SCN9A (0.52) | — | |
| SCHEMBL17886150 | 0.66 | SCN9A (0.44) | — | |
| SCHEMBL14790349 | 0.65 | SCN9A (0.47) | — | |
| SCHEMBL18856959 | 0.64 | HTR2C (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865719-B2 | Substituted heterocycles and their use as allosteric modulators of nicotinic and GABAA receptors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-10-21 | — | — | US | disclosed |
| US-20120077816-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINIC AND GABAA RECEPTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077816-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINIC AND GABAA RECEPTORS | CHRNA7, CHRNA5, CHRNA1 | MET 4368/4885CYP3A4 617/4885PDE1A 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.